Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT01191190 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

CLL

Interventions

DRUG: Ofatumumab/HDMP

Sponsor

Januario Castro, M.D.

Collaborators

[object Object]